NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous ...
Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, announced topline results from the CRESCENDO (Characterizing ...
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback